Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption

Endocrinologist

Volumn 10, Issue 1, 2000, Pages 18-26

  Dunstan, Colin R ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL TISSUE; BONE DISEASE; BONE MARROW CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE SRC; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL;

EID: 0033953432     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200010010-00005     Document Type: Review

References (55)

1. Rodan GA, Martin TJ: Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissue Int 1981; 33: 349-51.
2. Chambers TJ: The regulation of osteoclastic development and function. Ciba Found Symp 1988; 136: 92-107.
3. Takahashi N, Akatsu T, Udagawa N, et al.: Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988; 123: 2600-2.
4. Wiktor-Jedrzejczak W, Bartocci A, Ferramte AW, et al.: Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 1990; 87: 4828-32.
5. Yoshida H, Hayashi S, Kunisada T, et al.: The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345: 442-4.
6. Tondravi MM, McKercher SR, Anderson K, et al.: Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997; 386: 81-4.
7. Soriano P, Montgomery C, Geske R, Bradley A: Targetted disruption of the c-src proto-oncogen leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
8. Iotsova V, Caamano J, Loy J, Yang Y, Lewin B, Bravo R: Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med 1997; 3: 1285-9.
9. Johnson RS, Spiegelman BM, Papaioannou V: Pleiotropic effect of a null mutation in the c-fos proto-oncogene. Cell 1992; 71: 577-86.
10. Simonet WS, Lacey DL, Dunstan CR, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
11. Tsuda E, Goto M, Mochizuki S-I, et al.: Isolation of a novel cytokine from human fibroblasts that specifically inhibits bone osteoclastogenesis. Biochem Biophys Res Comm 1997; 234: 137-42.
12. Yamaguchi K, Kinosaki M, Goto M, et al.: Characterization of the structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998; 273: 5117-23.
13. Emery JG, McDonnell P, Burke MB, et al.: Osteoprotegerin is a receptor for the cyotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-7.
14. Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
15. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
16. Hakeda H, Kobayashi Y, Yamaguchi K, et al.: Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Comm 1998; 251: 796-801.
17. Burgess TL, Qian Y-X, Kaufman S, et al.: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-38.
18. Lum L, Wong BR, Josien R, et al.: Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274: 18613-8.
19. Fuller K, Wong B, Fox S, Choi YW, Chambers TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
20. Jimi E, Akiyama S, Tsurukai T, et al.: Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999; 163: 434-42.
21. Wong BR, Josien R, Lee SY, et al.: TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-80.
22. Anderson DM, Maraskovsky E, Billingsley WL, et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9.
23. Nakagawa N, Kinosaki M, Yamaguchi K, et al.: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Comm 1998; 253: 395-400.
24. Hsu H, Lacey DL, Dunstan CR, et al.: The TNFR related protein RANK is the osteoclast differentiation and activation receptor for osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-5.
25. Horwood NJ, Elliott J, Martin TJ, Gillespie MT: Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139: 4743-6.
26. Lee SK: Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999; 140: 3552-61.
27. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic proein-2 and cytokines. Biochem Biophys Res Comm 1998; 250: 776-81.
28. 2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Comm 1998; 246: 337-41.
29. 2 in human bone marrow stroma cells. Biochem Biophys Res Comm 1998; 247: 338-41.
30. Hofbauer LC, Gori F, Riggs BL, et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-9.
31. Vidal NOA, Brandstrom H, Jonsson KB, Ohlsson C: Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down regulation by glucocorticoids. J Endocrinol 1998; 159: 191-5.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140: 4367-70.
33. Takai H, Kanematsu M, Yano K, et al.: Transforming growth factor-β stimulates production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998; 273: 27091-6.
34. Murakami T, Yamamoto M, Yamamoto M, et al.: Transforming growth factor-beta 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Comm 1998; 252: 747-52.
35. Koide M, Murase Y, Yamato Y, Noguchi T, Okahashi N, Nishihara T: Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Comm 1999; 259: 97-102.
36. Vidal NOA, Sjogren K, Eriksson BI, Ljunggren O, Ohlsson C: Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in primary human osteoblast-like cells. Biochem Biophys Res Comm; 1998; 248: 696-700.
37. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Rigs BL, Khosla S: Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulated osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25: 255-9.
38. Brandstrom H, Jonsson KB, Vidal O, Ljunghall, S Ohlsson C, Ljunggren O: Tumor necrosis factor-α and β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Comm; 1998; 248: 454-7.
39. Bucay N, Sarosi I, Dunstan CR, et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
40. Mizuno A, Amizuka N, Irie K, et al.: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Comm 1998; 247: 610-5.
41. Kong Y-Y, Yoshida H, Sarosi I, et al.: OPGL is a key regulator or osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
42. 3. J Bone Miner Res 1999; 14: 1478-85.
43. Yamamoto M, Murakami T, Nishikawa M, et al.: Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998; 139: 4012-5.
44. Akatsu T, Murakami T, Onon K, et al.: Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998; 23: 495-8.
45. 2 cooperates with TRANCE in osteoclast induction for hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999; 140: 1927-1935.
46. Matsuzaki K, Udagawa N, Takahashi N, et al.: Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Comm 1998; 246: 199-204.
47. Shalhoub V, Faust J, Boyle WJ, et al.: Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 1999; 72:251-61.
48. Yano K, Tsuda E, Washida N, et al.: Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Research 1999; 14: 518-27.
49. Arrighi HM, Hsieh A, Wong V, et al.: Osteoprotegerin serum levels in healthy volunteers. Bone 1998; 23: S298.
50. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Dunstan CR: Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J Bone Mineral Res 1999; 14 (Suppl. 1) S180.
51. Tomoyasu A, Goto M, Fujise N, et al.: Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Comm 1998; 245: 382-7.
52. Whyte MP: Chipping away at marble bone disease. N Engl J Med 1995; 332: 1639-40.
53. Lomaga MA, Yeh, W. C, Sarosi I, et al.: TRAF6-deficient mice are osteopetrotic and defective in interleukin-1, interleukin-18, CD40 and LPS signaling. Genes Dev 1999; 13: 1015-24.
54. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y: The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 1998; 273: 28335-59.
55. Bachman MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y: TRANCE, a tumor necrosis factor family member critical for CE40 ligand-independent T helper cell activation. J Exp Med 1999; 189: 1025-31.